BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

232 related articles for article (PubMed ID: 20211871)

  • 1. Cardiac toxicity in association with chemotherapy and radiation therapy in a large cohort of older patients with non-small-cell lung cancer.
    Hardy D; Liu CC; Cormier JN; Xia R; Du XL
    Ann Oncol; 2010 Sep; 21(9):1825-1833. PubMed ID: 20211871
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Potential impact on survival of improved tumor downstaging and resection rate by preoperative twice-daily radiation and concurrent chemotherapy in stage IIIA non-small-cell lung cancer.
    Choi NC; Carey RW; Daly W; Mathisen D; Wain J; Wright C; Lynch T; Grossbard M; Grillo H
    J Clin Oncol; 1997 Feb; 15(2):712-22. PubMed ID: 9053497
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Improved survival in stage III non-small-cell lung cancer: seven-year follow-up of cancer and leukemia group B (CALGB) 8433 trial.
    Dillman RO; Herndon J; Seagren SL; Eaton WL; Green MR
    J Natl Cancer Inst; 1996 Sep; 88(17):1210-5. PubMed ID: 8780630
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of Chemotherapy Regimen and Radiation Modality on Hematologic Toxicities in Patients Receiving Definitive Platinum-based Doublet Chemoradiation for Non-Small Cell Lung Cancer.
    Tang C; Lee MS; Gomez D; Levy LB; Zhuang Y; Lu C; Liao Z; Komaki R
    Am J Clin Oncol; 2017 Dec; 40(6):625-630. PubMed ID: 26165417
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of amifostine on toxicities associated with sequential chemotherapy and radiation therapy for unresectable non-small-cell lung cancer: results of a phase II trial.
    Tannehill SP; Mehta MP; Larson M; Storer B; Pellet J; Kinsella TJ; Schiller JH
    J Clin Oncol; 1997 Aug; 15(8):2850-7. PubMed ID: 9256128
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Concurrent cetuximab and radiotherapy after docetaxel-cisplatin induction chemotherapy in stage III NSCLC: satellite--a phase II study from the Swedish Lung Cancer Study Group.
    Hallqvist A; Wagenius G; Rylander H; Brodin O; Holmberg E; Lödén B; Ewers SB; Bergström S; Wichardt-Johansson G; Nilsson K; Ekberg L; Sederholm C; Nyman J
    Lung Cancer; 2011 Feb; 71(2):166-72. PubMed ID: 20541833
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Acute esophagitis and late lung toxicity in concurrent chemoradiotherapy trials in patients with locally advanced non-small-cell lung cancer: analysis of the radiation therapy oncology group (RTOG) database.
    Werner-Wasik M; Paulus R; Curran WJ; Byhardt R
    Clin Lung Cancer; 2011 Jul; 12(4):245-51. PubMed ID: 21726824
    [TBL] [Abstract][Full Text] [Related]  

  • 8. High-dose conformal radiotherapy for treatment of stage IIIA/IIIB non-small-cell lung cancer: technical issues and results of a phase I/II trial.
    Rosenman JG; Halle JS; Socinski MA; Deschesne K; Moore DT; Johnson H; Fraser R; Morris DE
    Int J Radiat Oncol Biol Phys; 2002 Oct; 54(2):348-56. PubMed ID: 12243807
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Analysis of a novel protocol of combined induction chemotherapy and concurrent chemoradiation in unresected non-small-cell lung cancer: a ten-year experience with vinblastine, Cisplatin, and radiation therapy.
    Waters E; Dingle B; Rodrigues G; Vincent M; Ash R; Dar R; Inculet R; Kocha W; Malthaner R; Sanatani M; Stitt L; Yaremko B; Younus J; Yu E
    Clin Lung Cancer; 2010 Jul; 11(4):243-50. PubMed ID: 20630826
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A phase II study of concurrent chemoradiation with weekly docetaxel, carboplatin, and radiation therapy followed by consolidation chemotherapy with docetaxel and carboplatin for locally advanced inoperable non-small cell lung cancer (NSCLC).
    Jain AK; Hughes RS; Sandler AB; Dowlati A; Schwartzberg LS; Dobbs T; Schlabach L; Wu J; Muldowney NJ; Choy H
    J Thorac Oncol; 2009 Jun; 4(6):722-7. PubMed ID: 19404213
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Toxicity of combined radiation and chemotherapy in non-small cell lung cancer.
    Van Houtte P; Danhier S; Mornex F
    Lung Cancer; 1994 Mar; 10 Suppl 1():S271-80. PubMed ID: 8087520
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A phase II trial of concurrent chemoradiation therapy followed by consolidation chemotherapy with oral etoposide and cisplatin for locally advanced inoperable non-small cell lung cancers.
    Park J; Ahn YC; Kim H; Lee SH; Park SH; Lee KE; Lim DH; Park J; Kim K; Jung CW; Im YH; Kang WK; Lee MH; Park K
    Lung Cancer; 2003 Nov; 42(2):227-35. PubMed ID: 14568691
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy of combined radiation, paclitaxel and carboplatin for locally advanced non-small cell lung carcinoma.
    Nguyen NP; Leonardo JM; Karlsson U; Vos P; Bullock L; Thomas P; Lepera P; Ludin A; Chu C; Salehpour M; Jendrasiak G; Sallah S
    Anticancer Res; 2002; 22(6B):3429-35. PubMed ID: 12552935
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Neoadjuvant etoposide, ifosfamide, and cisplatin followed by concomitant thoracic radiotherapy and continuous cisplatin infusion in stage IIIb non-small cell lung cancer.
    Pujol JL; Lafontaine T; Quantin X; Reme-Saumon M; Cupissol D; Khial F; Michel FB
    Chest; 1999 Jan; 115(1):144-50. PubMed ID: 9925076
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of adding concurrent chemotherapy to hyperfractionated radiotherapy for locally advanced non-small cell lung cancer (NSCLC): comparison of RTOG 83-11 and RTOG 91-06.
    Komaki R; Scott C; Lee JS; Urtasun RC; Byhardt RW; Emami B; Andras EJ; Asbell SO; Rotman M; Cox JD
    Am J Clin Oncol; 1997 Oct; 20(5):435-40. PubMed ID: 9345325
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Patterns of disease failure after trimodality therapy of nonsmall cell lung carcinoma pathologic stage IIIA (N2). Analysis of Cancer and Leukemia Group B Protocol 8935.
    Kumar P; Herndon J; Langer M; Kohman LJ; Elias AD; Kass FC; Eaton WL; Seagren SL; Green MR; Sugarbaker DJ
    Cancer; 1996 Jun; 77(11):2393-9. PubMed ID: 8635112
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Population-based estimates of survival benefit associated with combined modality therapy in elderly patients with locally advanced non-small cell lung cancer.
    Davidoff AJ; Gardner JF; Seal B; Edelman MJ
    J Thorac Oncol; 2011 May; 6(5):934-41. PubMed ID: 21372743
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Addition of chemotherapy improves overall survival in patients with T2N0M0 non-small cell lung cancer undergoing definitive radiation therapy: An analysis of the SEER database.
    Komiya T; Chaaya G; Powell E
    Radiother Oncol; 2019 Feb; 131():75-80. PubMed ID: 30773190
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Feasibility of high-dose three-dimensional radiation therapy in the treatment of localised non-small-cell lung cancer.
    Bellière A; Girard N; Chapet O; Khodri M; Kubas A; Souquet PJ; Mornex F
    Cancer Radiother; 2009 Jul; 13(4):298-304. PubMed ID: 19525134
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Adjuvant chemotherapy for elderly patients with stage I non-small-cell lung cancer ≥4 cm in size: an SEER-Medicare analysis.
    Malhotra J; Mhango G; Gomez JE; Smith C; Galsky MD; Strauss GM; Wisnivesky JP
    Ann Oncol; 2015 Apr; 26(4):768-773. PubMed ID: 25600562
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.